These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35631632)

  • 1. Chitooligosaccharides Improve the Efficacy of Checkpoint Inhibitors in a Mouse Model of Lung Cancer.
    Johansen AZ; Carretta M; Thorseth ML; Khan S; Fjæstad KY; Brøchner CB; Linder H; Ankjærgaard C; Donia M; Chen I; Nielsen DL; Behrens CP; Madsen DH
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy.
    Johansen AZ; Novitski SI; Hjaltelin JX; Theile S; Boisen MK; Brunak S; Madsen DH; Nielsen DL; Chen IM
    Front Immunol; 2023; 14():1228907. PubMed ID: 37744345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do Elevated YKL-40 Levels Drive the Immunosuppressive Tumor Microenvironment in Colorectal Cancer? Assessment of the Association of the Expression of YKL-40, MMP-8, IL17A, and PD-L1 with Coexisting Type 2 Diabetes, Obesity, and Active Smoking.
    Ochman B; Mielcarska S; Kula A; Dawidowicz M; Robotycka J; Piecuch J; Szrot M; Dzięgielewska-Gęsiak S; Muc-Wierzgoń M; Waniczek D; Świętochowska E
    Curr Issues Mol Biol; 2023 Mar; 45(4):2781-2797. PubMed ID: 37185706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma levels of the proinflammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene (CHI3L1), and incident cardiovascular events.
    Ridker PM; Chasman DI; Rose L; Loscalzo J; Elias JA
    J Am Heart Assoc; 2014 Jun; 3(3):e000897. PubMed ID: 24958781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The chitinase-like protein YKL-40 is secreted by airway epithelial cells at base line and in response to compressive mechanical stress.
    Park JA; Drazen JM; Tschumperlin DJ
    J Biol Chem; 2010 Sep; 285(39):29817-25. PubMed ID: 20650887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitinase 3-like protein 2 (CHI3L2, YKL-39) activates phosphorylation of extracellular signal-regulated kinases ERK1/ERK2 in human embryonic kidney (HEK293) and human glioblastoma (U87 MG) cells.
    Areshkov PA; Kavsan VM
    Tsitol Genet; 2010; 44(1):3-9. PubMed ID: 20201406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chitinase-3-like-1/YKL-40 as marker of circulating tumor cells.
    Hamilton G; Rath B; Burghuber O
    Transl Lung Cancer Res; 2015 Jun; 4(3):287-91. PubMed ID: 26207216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YKL-39 as a Potential New Target for Anti-Angiogenic Therapy in Cancer.
    Kzhyshkowska J; Larionova I; Liu T
    Front Immunol; 2019; 10():2930. PubMed ID: 32038607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer.
    Luo F; Lu FT; Cao JX; Ma WJ; Xia ZF; Zhan JH; Zeng KM; Huang Y; Zhao HY; Zhang L
    Cancer Lett; 2022 Apr; 531():39-56. PubMed ID: 35090965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review.
    Naltet C; Besse B
    Transl Lung Cancer Res; 2021 Jun; 10(6):3014-3028. PubMed ID: 34295694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
    Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
    Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
    [No Abstract]   [Full Text] [Related]  

  • 17. Partially acetylated chitooligosaccharides bind to YKL-40 and stimulate growth of human osteoarthritic chondrocytes.
    Einarsson JM; Bahrke S; Sigurdsson BT; Ng CH; Petersen PH; Sigurjonsson OE; Jonsson H; Gislason J; Thormodsson FR; Peter MG
    Biochem Biophys Res Commun; 2013 May; 434(2):298-304. PubMed ID: 23541584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers.
    Faibish M; Francescone R; Bentley B; Yan W; Shao R
    Mol Cancer Ther; 2011 May; 10(5):742-51. PubMed ID: 21357475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
    Bissonnette RP; Cesario RM; Goodenow B; Shojaei F; Gillings M
    BMC Cancer; 2021 Aug; 21(1):969. PubMed ID: 34461854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
    Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
    J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.